Flash-Player installieren
ScheBo-MediaBox



» Flash-Player installieren
» Watch video in bigger size

ScheBo® · Biotech AG
Netanyastrasse 3
35394 Giessen
Germany

Phone +49 (0)641 / 4996-0
Fax +49 (0)641 / 4996-77
Email-contact

ScheBo® Pancreatic Elastase 1™ Stool Test

The new gold standard for non-invasive pancreatic function testing


Abdominal Pain - Maldigestion - Malassimilation - Chronic Pancreatitis - Cystic Fibrosis - Post-traumatic injuries

Is the pancreas involved?

The reliable and cost-effective ScheBo® Pancreatic Elastase 1™ Stool Test gives you the answer.

The new gold standard!

The test is the new gold standard for non-invasive pancreatic function testing. It has been evaluated in comparisons with the invasive secretin-pancreozymin and secretin-caerulein tests.

Human pancreatic elastase 1 (E1) remains undegraded during intestinal transit. Therefore its concentration in faeces reflects pancreatic exocrine function. The diagnostic efficiency of pancreatic elastase 1 determination in stool has been evaluated in several clinical studies. Stein et al. (1993 & 1996, 1997) and Löser et al. (1995 & 1996) compared the E1 determination with invasive intubation tests, the secretin-pancreozymin test and the secretin-caerulein test, respectively. Both authors report a sensitivity and specificity greater than 90% for the diagnosis of exocrine pancreatic insufficiency. On contrast to the fecal chymotrypsin assay, even a moderate pancreatic insufficiency can be detected by E1 determination (Löser et al., 1995 & 1996, Gullo et al., 1999).
In addition, studies by Terbrack et al. (1996), Soldan et al. (1996), Gullo et al. (1999), Wallis et al. (1997), Walkowiak et al. (1999) and Cade et al. (2000) showed an excellent sensitivity and specificity for the diagnosis of cystic fibrosis with pancreatic involvement.


AEO-Certificate
The Main Customs Office of Giessen, Germany issued an AEO-F Certificate (Authorized Economic Operator – Customs Simplifications plus Security and Safety) to ScheBo Biotech AG on September 30, 2011.
read...
Lecture DDW 2011: New molecular markers: M2-PK
Lecture of Prof. Dr. Sybille Mazurek on WEO/OMED Colorectal Cancer Screening Committee Meeting DDW 2011.
read...
Biomarker ′M2-PK′ Identified as Key Enzyme in Cancer Diagnosis and Therapy
Ground Breaking Findings on Understanding Cancer Published in ′Science′
read...
Video: Focus 2010 lecture on M2-PK
The high sensitivity (c.80%) and high specificity (>90%) of the M2-PK stool test for colorectal cancer screening and detection, plus benefits for patients, laboratories and doctors, was presented at Focus 2010
read...
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
read...
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.
read...
ISO-Certificate
Our ISO-Cerficate as pdf-download.
read...